Amarin (AMRN) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Rocket Pharmaceuticals (RCKT) has outperformed Amarin (AMRN) over the past year, losing 41.2% versus a loss of 42.4%. Over five years, AMRN leads with a -88.7% price change compared with -92.6% for RCKT. Rocket Pharmaceuticals is the larger company by market cap ($239.3 million vs $239.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | RCKT |
|---|---|---|
| Share price | $11.32 | $2.18 |
| Market cap | $239.11M | $239.31M |
| 1-day change | -2.16% | -7.63% |
| YTD return | -18.91% | -37.89% |
| 1-year return | -42.36% | -41.24% |
| 5-year return | -88.68% | -92.58% |
| Forward P/E | 11.55 | — |
| EPS (TTM) | $-1.20 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $213.65M | $0 |
| Revenue growth (YoY) | -6.55% | — |
| Net income (latest FY) | $-38.80M | $-223.12M |
| Gross margin | 56.57% | — |
| Operating margin | -23.48% | — |
| Net margin | -18.16% | — |
| 52-week high | $20.90 | $5.45 |
| 52-week low | $11.25 | $2.17 |
| Distance from 52-week high | -45.84% | -60.00% |
| Analyst consensus | none | buy |
| Avg. price target upside | +10.42% | +293.58% |
| Average volume | 66.71K | 1.77M |
| Shares outstanding | 21.12M | 109.77M |
| Employees | 80 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
AMRN vs RCKT FAQ
Which is bigger, Amarin or Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $239.31M compared with $239.11M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or RCKT?
RCKT returned -41.24% over the past 12 months, compared with -42.36% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.